Altre lingue FluoGuide A/S

Azioni

FLUO

DK0061123312

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 16:41:57 24/04/2024			Variaz. 5gg	Var. 1 gen.
48,2 ^SEK	+9,79%		+8,19%	-21,24%

20/03	FluoGuide A/S approva i cambiamenti del Consiglio di Amministrazione	CI
12/03	FluoGuide A/S entra in collaborazione con Intuitive Surgical, Inc. nell'ambito della chirurgia oncologica della testa e del collo assistita da robot.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

FluoGuide A/S Approves Board Changes	20/03
Minutes from Annual General Meeting in FluoGuide A/S	20/03
Chief Financial Officer (CFO) Ole Larsen buys shares	13/03
FluoGuide enters collaboration within robot assisted head and neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company	12/03
FluoGuide A/S Enters Collaboration Within Robot Assisted Head and Neck Cancer Surgery with Intuitive Surgical, Inc	12/03
Notice of Annual General Meeting in FluoGuide A/S	01/03
Fluoguide Q4 2023 - Bright prospects	28/02
FluoGuide A/S publishes year-end and annual report for the fiscal year 2023	28/02
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
FluoGuide A/S issues warrants to CFO	23/02
FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001	08/01
FluoGuide provides strategic update and outlines development plans towards commercialization of FG001	08/01
FluoGuide raises SEK 12 million through exercise of warrants	11/12
Chief Development Officer (CDO) Grethe Nørskov Rasmussen sells shares	09/12
FluoGuide raises SEK 12 million through exercise of warrants	08/12
Fluoguide Q3 2023 - Spoilt for choice	29/11
FluoGuide A/S publishes interim report for the period January – September 2023	29/11
FluoGuide A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11
FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer	13/11
FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer	13/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue FluoGuide A/S

Azioni

FLUO

DK0061123312

Altre lingue

Filtri